MedTrace Logo

Using Mirabegron to Increase BP in Patients With POTS

NCT06133075 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-04-08

Study results available
· View outcomes & findings →

Summary

This is a pilot dose-finding study to test the hypothesis that mirabegron increases systolic blood pressure (BP), prevents syncope/presyncope, and improves the quality of life (QOL), functional capacity, chest pain, and overactive bladder (OAB) symptoms in patients with postural orthostatic tachycardia syndrome (POTS) who have a documented history of hypotension inadequately responsive to conventional treatments. The American Heart Association funds this study.

Conditions

  • Postural Orthostatic Tachycardia Syndrome
  • Chronic Orthostatic Intolerance
  • Syncope

Interventions

DRUG

Mirabegron 50 MG

10 patients will receive drug for 8 weeks

DRUG

Mirabegron 25 MG

10 patients will receive drug for 8 weeks

Sponsors & Collaborators

  • Cedars-Sinai Medical Center

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-22
Primary Completion
2025-05-20
Completion
2025-07-25
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06133075 on ClinicalTrials.gov